Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.
about
Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infectionAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewOsteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone LossRANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapiesOPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in miceBiomarkers predicting a need for intensive treatment in patients with early arthritisCytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis.T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritisThe expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1.Role of polyethylene particles in peri-prosthetic osteolysis: A review.Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexateInterleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes.Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosisBaseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis.Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritisRANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritisRheumatic diseases: the effects of inflammation on bone.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints.Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium.Synovial tissue heterogeneity and peripheral blood biomarkers.Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.Regulation of TNF-α with a focus on rheumatoid arthritis.The role of interleukin-17A in psoriatic disease.Mediators of inflammation and bone remodeling in rheumatic disease.Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis.The role of stromal cells in inflammatory bone loss.Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.Bone Wasn't Built in a Day: Destruction and Formation of Bone in the Rheumatic Diseases.Inflammatory cells and bone loss in rheumatoid arthritis.Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts.MSRA polymorphism is associated with the risk of rheumatoid arthritis in a Chinese population.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review.Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis.Human circulating monocytes can express receptor activator of nuclear factor-kappaB ligand and differentiate into functional osteoclasts without exogenous stimulation.
P2860
Q24701763-8D67CF53-4FDB-4480-B9AA-81D7E83551F1Q26774874-7243EEC2-F190-4A0C-9C38-BD947E8D5A5BQ27008993-E5A80055-49E2-4105-B206-881C5A0B6BE8Q28570898-FFDFCE66-9B21-46FC-BD08-2046F7E1A40DQ33730470-13409CEE-6696-4EB7-B598-B08A7A2E039EQ34982012-C06F5A1C-1C10-479F-A0B5-AFAE1DE16361Q35249619-D838A993-F8D3-4FCA-AAFB-AA2D8D54D22FQ35554105-87CFC037-5714-4523-AC10-4D89820B5268Q35617622-6EC2DCCE-42CE-4A5A-AE4D-88E16F827069Q35825373-062D83EA-9D96-49EA-BFB0-992995E8C861Q36027446-7C3D5554-5E93-48A9-B4BA-E67C86214245Q36101730-01A8C1AC-CEDA-4646-8F80-0843DC0634BBQ36144864-0E04376C-3413-442D-BBC0-6EF60C3A51ADQ36171870-9EE09F11-206F-41A2-9FD0-F22D353623DCQ36211891-FB92E31C-79DA-4CAA-9D18-E3495777F87DQ36246077-3F150626-B48A-4184-8992-FC85DA87AB59Q36246148-33A93BD8-EE52-4061-B5D6-1FBFD5085558Q36324975-B3BAB094-7867-43DB-A64C-210A60E4FDCBQ36860987-12211D7E-406E-49C2-A63A-0A702ED66EB7Q36903327-F4ACE7E2-3AF0-4AF2-B07D-E053E0CB969FQ36907683-02138C96-651A-4B37-9B98-B94D50D47F32Q37207081-ADCE1C43-15A8-4798-8E12-7565711959D2Q37918858-FB0103D3-8A69-41D4-B549-8AEBDEDD3AE4Q38076074-C0DD44E6-2B4B-4B41-BDAA-0A344B65943AQ38102876-6B6D7DC9-C43C-4C49-BB86-A74AB676FE6CQ38217029-BCEC9E9F-EEC0-4314-99C8-E90A11C6D93FQ38576851-6A4DA159-AF43-4104-B556-0460495F8EC9Q38991582-19E17D3B-D5BC-4B38-AD76-218D0F0F16C9Q39248512-B03E24E0-DFF9-4760-826F-25064BA3BB25Q39998140-BA6B47E2-DF97-40A5-BE94-9FB3BFE321C6Q41112237-65AE7F33-405E-4774-8AF1-69403B7874B1Q42549439-A8F1C8E1-620A-4791-87DF-CA0F6B424D5EQ43049903-F055C536-3BF2-4382-A497-9E3C67A3B165Q46469299-99145D61-5991-48A8-B811-D465BCDB1A85Q47800990-F3D6A8D3-4C8C-4847-9747-34336B6CFD49Q47973046-52D633E3-C72B-4A9D-A75C-AE8D79719B43Q50142964-A791B69D-923F-4215-A129-2A9C6F7D0BAFQ50607910-18E6D530-E39B-4BCC-8D9B-0B69BA2DC468Q51151290-134EB947-B4BD-4EF1-8060-EADC06C47897Q53495905-1A47FE40-2621-40AF-B37C-7A061BB99E74
P2860
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@ast
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@en
type
label
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@ast
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@en
prefLabel
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@ast
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@en
P2093
P2860
P356
P1476
Receptor activator NF-kappaB l ...... ive and quantitative analysis.
@en
P2093
Findlay DM
P2860
P304
P356
10.1136/ARD.61.12.1047
P407
P577
2002-12-01T00:00:00Z